story of the week
Safety and Efficacy of Continuous Subcutaneous Foslevodopa–Foscarbidopa in Patients With Advanced Parkinson's Disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Neurology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial
Lancet Neurol 2022 Dec 01;21(12)1099-1109, MJ Soileau, J Aldred, K Budur, N Fisseha, VS Fung, A Jeong, TE Kimber, K Klos, I Litvan, D O'Neill, WZ Robieson, MA Spindler, DG Standaert, S Talapala, EO Vaou, H Zheng, MF Facheris, RA HauserFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.